๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 44 Guangzhou 29 Shanghai 25 Tianjin 22 Hangzhou 20
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing44 Guangzhou29 Shanghai25 Tianjin22 Hangzhou20
All 57 locations
Target enrolment
to

Trials with a site in Nanjing

16 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
Hoffmann-La Roche
Phase 3
380
Guangzhou, Nanjing, Qingdao, Kunming, Hangzhou, Jinan, Nanning, Shanghai
2026-06-23
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
NCT07663253Multiple Myeloma
Shanghai Zhongshan Hospital
Observational
333
Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing
2026-06
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
400
Beijing, Chengdu, Guangzhou, Hangzhou, Nanjing, Nanning, Shanghai, Wenzhou
2026-02-04
Recruiting
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
36
Zhengzhou, Nanjing, Xuzhou, Shanghai, Xiโ€™an
2025-12-10
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Recruiting
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
NCT06083207Multiple Myeloma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
116
Beijing, Nanning, Wuhan, Nanjing, Suzhou, Xuzhou, Nanchang, Shanghai
2024-07-29
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
AbbVie
Phase 3
421
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2024-05-19
Recruiting
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
NCT06497738Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Observational
112
Changzhou, Nanjing, Nantong, Taizhou, Yancheng
2024-05-01
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Not yet open
A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
NCT05181501Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
20
Hefei, Changzhou, Nanjing
2022-04
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
Pfizer
Phase 3
893
Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2021-10-04
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Nanjing that also match the filters currently applied.

How many clinical trials are recruiting in Nanjing?

11 of the 16 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanjing), 16 studies
PhaseStudiesRecruitingShare
Phase 39556.3%
Observational2212.5%
Phase 12112.5%
Phase 1/2116.3%
Phase 4116.3%
Phase EARLY_PHASE1116.3%

Most active sponsors

Lead sponsors with the most studies (Nanjing)
Lead sponsorStudiesRecruiting
AbbVie20
GlaxoSmithKline21
Janssen Research & Development, LLC22
Pfizer22
The First Affiliated Hospital with Nanjing Medical University22
Bristol-Myers Squibb10
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.11
Hoffmann-La Roche11
Innovent Biologics (Suzhou) Co. Ltd.11
Nanjing IASO Biotechnology Co., Ltd.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.